Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $320
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $275 to $320.
August 02, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer maintains a Buy rating on Alnylam Pharmaceuticals and raises the price target from $275 to $320.
The raised price target and maintained Buy rating from a reputable analyst are likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100